Texas Collaboration Pioneers Breakthrough in Oral Healthcare with BioViscid™

A groundbreaking collaboration among Shear Kershman Laboratories, Texas A&M University College of Dentistry, and Innovative MedTech Inc. is set to revolutionize oral healthcare through the development of BioViscid™, a novel bio-adhesive formulation aimed at treating oral thrush with unmatched efficacy. This partnership, solidified by a Memorandum of Understanding (MOU), targets the creation of innovative medical solutions that promise to transform patient care for a condition affecting 5-7% of Americans, especially those with weakened immune systems.

BioViscid™ stands out from current treatments by employing a sustained-release mechanism that directly adheres to mucosal tissues, maintaining therapeutic effectiveness for 6-8 hours after application, even in moist environments. This targeted approach avoids the first-pass metabolism associated with systemic treatments like fluconazole, offering a more efficient and patient-friendly solution.

The global market for oral candidiasis treatments, valued at $4-6 billion, presents a substantial opportunity for growth. This collaboration not only aims to tackle the pressing challenges in oral health but also seeks to pioneer advancements in drug delivery systems for oral diseases and underserved healthcare populations. Dr. Lily T. Garcia, Dean of Texas A&M College of Dentistry, highlights the partnership's potential to merge science, technology, and patient care into impactful innovations.

With objectives that include the joint development of cutting-edge technologies, the enhancement of academic training programs, and the conduction of pioneering research, this alliance is poised to make significant strides in improving global patient outcomes. The implications of this partnership extend far beyond oral thrush treatment, heralding a new era of medical innovation and healthcare solutions.